Phase 2 Uveitis Trial, Recruiting NCT07552012 Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Condition: Uveitis
Back to Uveitis

Phase 2 Uveitis Trial, Recruiting

NCT07552012
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to understand the trial procedures, are willing to take part, can communicate with the research team, and are able to follow all study requirements, including signing a consent form.
  • You are between 18 and 70 years old (inclusive) at the screening visit.
  • At the screening visit, your Body Mass Index (BMI) is between 18 and 30, and you weigh at least 50 kg (if male) or at least 45 kg (if female).
  • At least one of your eyes has been diagnosed by the study doctor with active non-infectious uveitis (inflammation inside the eye that is not caused by infection), specifically of the middle, back, or whole eye.
  • Your eye condition is still active despite taking a steady dose of steroid tablets (such as prednisone) for at least 2 weeks, shown by at least one of the following: active inflammatory lesions in the back of the eye, significant inflammation in the front chamber of the eye, or significant cloudiness in the jelly-like substance inside the eye.
  • You and your partner agree not to try to have a baby, or donate sperm or eggs, from the start of the trial until at least one month after your last dose of the study drug, and you agree to use an effective form of contraception during this time.

Who may not be able to join:

  • You have uveitis that only affects the front part of the eye (anterior uveitis only).
  • The only sign of your uveitis is swelling at the centre of the back of the eye (macular oedema), with no other signs of inflammation.
  • You have uveitis caused by an infection, such as tuberculosis, cytomegalovirus, Lyme disease, toxoplasmosis, or certain other infections.
  • You have a condition called Histoplasmosis Syndrome affecting the eye.
  • Your eye condition is caused by something other than true inflammation, such as injury, cancer (including lymphoma), or previous surgery (confirm with trial site).
  • You have a specific eye condition called serpiginous choroidopathy.
  • You have cloudiness of the cornea or lens in either eye that makes it hard to examine the back of the eye, or that is likely to need cataract surgery during the trial.
  • You have severe cloudiness of the jelly-like substance inside the eye, or any other problem that makes it impossible to see the back of the eye clearly in either eye.
  • You have poorly controlled glaucoma (high pressure in the eye of 25 mmHg or more), are already using two or more glaucoma medications, or have signs of damage to the optic nerve from glaucoma.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-23-89011876

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Registry
ClinicalTrials.gov
Start date
29 January 2026
Est. completion
28 February 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The percentage of patients meeting treatment failure criteria from week 6 to week 24.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov